BrainChild Bio secures $116M for pediatric brain tumor CAR-T therapy
A company developing an autologous CAR-T cell therapy for a rare, aggressive brainstem cancer in children has closed a $116 million Series A. The funding will support a pivotal trial for its lead candidate, targeting diffuse intrinsic pontine glioma (DIPG).
Sources: genengnews.com
“This funding round stands out for its focus on a pediatric CNS tumor, a niche where clinical and financial risks are high but unmet needs are acute.”
What it means
CAR-T therapies have primarily advanced in blood cancers, making this push into solid tumors—and pediatric ones at that—notable. Success in DIPG could open doors for similar approaches in other hard-to-treat CNS malignancies, though scalability and cost remain hurdles. The size of the Series A suggests strong investor confidence, but execution will be critical in a field with few precedents.
Read the original reporting
The outlets below did the original reporting.
Related briefs
- Simple Energy’s $180M round drives India’s weekly funding surge
- Shionogi backs Celaid’s Series B, hinting at deeper biotech ties
- Celaid closes Series B second tranche, total haul undisclosed
- Snapdeal’s muted IPO raises questions about India’s ecommerce moats
- doxx.net raises $38M to build private networks for AI agents
This brief was drafted automatically from the sources above and published under our editorial policy. Spotted an error? Tell us.